

**IN THE CLAIMS:**

Claims 1-67 and 76 were previously cancelled. Claim 77 is herein cancelled. Claims 68-75 have been amended herein. New claim 78 is presented herein. All of the pending claims are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

**Listing of the Claims:**

1.-67. (Cancelled)

68. (Currently amended) A method for stimulating an immune response ~~directed towards an antigen in an individual~~, said method comprising administering ~~the antigen to said an individual~~ who has been exposed to or is at risk of exposure to a first antigen a composition comprising a conjugate of the first antigen and at least one second antigen, wherein the at least one second antigen comprises, ~~wherein the antigen is covalently attached to at least one non-sialyated Lewis x antigen to from a glycoconjugate, and thereby targeting the antigen to a C-type lectin receptor on an antigen presenting cell of said individual.~~

69. (Currently amended) [[A]] The method according to claim 68, wherein said first antigen is a peptide or glycolipid capable of being presented in the context of MHC class I or class II or C1b.

70. (Currently amended) [[A]] The method according to claim 69, wherein said first antigen is selected form the group consisting of a pathogen antigen, a tumor antigen, a cell associated receptor antigen, an autoimmune antigen, a self-antigen and a C-type lectin binding part thereof.

71. (Currently amended) [[A]] The method according to claim 69, wherein said first antigen is a pathogen or a tumor antigen.

72. (Currently amended) [[A]] The method according to claim 71, wherein said pathogen is selected from the group consisting of a virus, a fungus, and a bacterium.

73. (Currently amended) [[A]] The method according to claim 71, wherein said pathogen is a mycobacterium or a parasite.

74. (Currently amended) [[A]] The method according to claim 71, wherein said pathogen is selected from the group consisting of a Human Immunodeficiency Virus, a *Helicobacter*, a *Neisseria meningitides*, a *Leishmania*, a *Schistosoma*, a *Klebsiella*, a probiotic *Lactobacillus*, Hepatitis C Virus, a Herpes simplex virus and an Ebola virus.

75. (Currently amended) [[A]] The method according to claim 68, wherein said C-type lectin receptor is DC-SIGN.

76. (Cancelled).

77. (Cancelled).

78. (New) A method of generating a immune response, the method comprising:  
administering a composition comprising a first antigen capable of eliciting an immune response conjugated to at least one second antigen, wherein the at least one second antigen comprises at least one Lewis x antigen.